XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three months ended March 31, 2023 and 2022 were as follows:
Three Months Ended
(in millions)20232022
Equipment & Instruments$152 $166 
CAD/CAM105 106 
Orthodontics86 68 
Implants137 155 
Healthcare68 70 
Technology & Equipment segment revenue$548 $565 
Endodontic & Restorative$313 $293 
Other Consumables117 111 
Consumables segment revenue$430 $404 
Total net sales$978 $969 

Net sales disaggregated by geographic region for the three months ended March 31, 2023 and 2022 were as follows:
Three Months Ended
(in millions)20232022
United States$351 $308 
Europe396 411 
Rest of World231 250 
Total net sales$978 $969 

Contract Assets and Liabilities

The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had $93 million and $84 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets at March 31, 2023 and December 31, 2022, respectively. The Company recognized approximately $32 million of revenue during the current year which was previously deferred as of December 31, 2022. The Company expects to recognize a significant majority of the remaining deferred revenue within the next twelve months.

Allowance for Doubtful Accounts

Accounts and notes receivables-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $11 million at March 31, 2023 and $14 million at December 31, 2022. For the three months ended March 31, 2023 and 2022, changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.